Your browser doesn't support javascript.
loading
Pembrolizumab-Induced Pancreatic Exocrine Insufficiency Complicated by Severe Hepatic Steatosis.
Hong, Alex S; Sarwar, Naveed; Goldin, Robert D; Dhar, Ameet; Possamai, Lucia A.
Afiliação
  • Hong AS; Gastroenterology and Hepatology, Imperial College School of Medicine, London, GBR.
  • Sarwar N; Medical Oncology, Department of Oncology, Imperial College Healthcare NHS Trust, Charing Cross Hospital, London, GBR.
  • Goldin RD; Section for Pathology, Department of Metabolism, Digestion and Reproduction, Imperial College London, London, GBR.
  • Dhar A; Gastroenterology and Hepatology, Department of Hepatology, Imperial College Healthcare NHS Trust, St. Mary's Hospital, London, GBR.
  • Possamai LA; Gastroenterology and Hepatology, Department of Hepatology, Imperial College Healthcare NHS Trust, St. Mary's Hospital, London, GBR.
Cureus ; 14(7): e26596, 2022 Jul.
Article em En | MEDLINE | ID: mdl-35936135
Anti-programmed death receptor-1 (anti-PD-1) monoclonal antibodies (mAbs) are used to treat an increasing range of cancers. However, the distinct toxicity profile of immune-related adverse events (irAEs) is a frequent drawback of their clinical application. Among the more common irAEs are hepatitis and colitis, which are diagnosed and graded in patients based on elevated serum liver enzyme levels and increased stool frequency, respectively, and both of which often require treatment with high-dose corticosteroids. Herein, we describe the case of a patient who developed severe transaminase elevation and diarrhoea due to an unusual irAE, which was successfully treated without corticosteroids.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Ano de publicação: 2022 Tipo de documento: Article